Security
Ping An Biomedical Co., Ltd. Class A Ordinary Shares · PASW
PASWNASDAQCommon stockCurrentCIK 1897532Updated Nov 2, 2026
Name history
Majestic Ideal Holdings Ltd · through Sep 29, 2025
PASW price & chart
Loading TradingView…
NASDAQ:PASW on TradingView ↗About the company
We are a provider of SCM services in the apparel industry delivering one-stop solution to our customers for a broad range of yarn products, textiles and finished garments. We conduct our operations through our PRC subsidiary New Brand, which is headquartered in Hong Kong. Our service offerings encompass every key aspect of the supply chain of these products: market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. Through our integrated capabilities, we provide end-to-end supply chain solutions that are tailored to meet our customers’ unique needs.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2025 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 6,700,990Source | — | 9,610,131Source |
| Property, Plant and Equipment | —Source | — | — |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,110Source | — | 164,697Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 4,134,576Source | — | 2,378,266Source |
| Inventory, NetUSD | 18,236Source | — | 62,074Source |
| Assets, CurrentUSD | 6,348,058Source | — | 8,947,527Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,853,812Source | — | 1,352,490Source |
| Operating Lease, Right-of-Use AssetUSD | 90,948Source | — | 65,680Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 8,319,657Source | — | 3,255,025Source |
| Stockholders’ equity: | |||
| Common Stock, Value, IssuedUSD | 1,002Source | — | 1,180Source |
| Retained Earnings (Accumulated Deficit)USD | -1,715,839Source | — | -2,956,513Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -135,261Source | — | -226,297Source |
| Stockholders' Equity Attributable to ParentUSD | -1,618,667Source | -5,558,302Source | 6,355,106Source |
| Additional Paid in Capital, Common StockUSD | — | — | 9,300,828Source |
| Liabilities and EquityUSD | 6,700,990Source | — | 9,610,131Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 8,279,773Source | — | 3,241,582Source |
| Operating Lease, Liability, CurrentUSD | 51,064Source | — | 52,238Source |
| Accounts Payable, CurrentUSD | 913,978Source | — | 1,322,294Source |
| Operating Lease, Liability, NoncurrentUSD | 39,884Source | — | 13,443Source |
cash flow · annual statements
| Line item | Q2 2025 | Q2 2024 | FY 2025 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | -1,990,054Source |
| Increase (Decrease) in InventoriesUSD | — | — | 43,331Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | -792,584Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | -902,902Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesCNY | — | — | 0Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | 6,132,944Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 15,110Source | 969,621Source | 5,154,697Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 43,671Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | -93,736Source |
| Additional Financial Items | |||
| DepreciationUSD | — | — | 785Source |
| General and Administrative ExpenseUSD | — | — | 843,909Source |
| Income Tax Expense (Benefit)USD | — | — | 260,653Source |
| InterestExpenseNonoperatingUSD | — | — | 43,132Source |
| Inventory Write-downCNY | — | — | 6,135Source |
| Investment Income, InterestUSD | — | — | 45,842Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,802,108Source |
| Nonoperating Income (Expense)USD | — | — | 2,342Source |
| Operating ExpensesUSD | — | — | 2,198,479Source |
| Operating Lease, ExpenseUSD | — | — | 54,630Source |
income statement · annual statements
| Line item | FY 2025 |
|---|---|
| Total RevenueUSD | 4,796,732Source |
| Cost of Goods and Services Sold | —Source |
| Operating Income (Loss)USD | -2,065,103Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -2,062,761Source |
| Income Tax Expense (Benefit)USD | 260,653Source |
| Net Income (Loss) Attributable to ParentUSD | -1,802,108Source |
| Earnings Per Share, BasicUSD per share | -0.1Source |
| Earnings Per Share, DilutedUSD per share | -0.1Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 18,479,452Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 18,479,452Source |
| Interest Expense (non-operating)USD | 43,132Source |
| Additional Financial Items | |
| Current Income Tax Expense (Benefit)USD | 46,119Source |
| General and Administrative ExpenseUSD | 843,909Source |
| Gross ProfitUSD | 133,376Source |
| Investment Income, InterestUSD | 45,842Source |
| Nonoperating Income (Expense)USD | 2,342Source |
| Operating ExpensesUSD | 2,198,479Source |
| Operating Lease, ExpenseUSD | 54,630Source |
| Selling and Marketing ExpenseUSD | 42,135Source |
Offerings
Registration 333-299624
Registration 333-293481
Filing attachments
ea030949201ex99-1.htm · 6-K · 2026-10-26
Exhibit 99.1 Ping An Biomedical Announces Planned Acquisition of Three Tumor Cell-Related Medical Technology Patents to Build a Core Oncology and Biotech Intellectual Property Portfolio FOR IMMEDIATE RELEASE HONG KONG, October 22, 2026 - Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (the “Company”) today announced its entry into a letter of intent with Future Biotechnology Group Co., Limited (the “Letter of Intent”), for the planned acquisition (the “Planned Acquisition”) of three tumor cell-re…
Read attachment ↗ea030768201ex99-1.htm · 6-K · 2026-10-22
Exhibit 99.1 Ping An Biomedical Co., Ltd.平安生物医药有限公司22/F, China United Plaza, 1002-1008, Tai Nan West Street, Cheung Sha Wan, Kowloon, Hong Kong NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To the shareholders of October 22, 2026 Ping An Biomedical Co., Ltd. 平安生物医药有限公司 Hong Kong ───────────────────────────────────────────────────────────────── Dear Shareholder: NOTICE IS HEREBY GIVEN that an Extraordinary General Meeting of Shareholders (the “Meet…
Read attachment ↗ea030768201ex99-2.htm · 6-K · 2026-10-22
Exhibit 99.2 SPECIMEN 1 MAIN STREET ANYWHERE PA 99999-9999 VOTE BY INTERNET Go to https://ts.vstocktransfer.com/pxlogin and log in using the below control number. Voting will be open until 11:59 p.m., Eastern Time, October 27, 2026. CONTROL VOTE BY MAIL Mark, sign and date your proxy card and return it in the envelope we have provided. VOTE IN PERSON If you would like to vote in person, please attend the Extraordinary General Meeting to be held at 10 P.M., Hong Kong Time, on October 29, 2026, a…
Read attachment ↗ea030613201ex99-1.htm · 6-K · 2026-10-21
Exhibit 99.1 Ping An Biomedical Announces 1-for-40 Reverse Stock Split Class A Ordinary Shares Expected to Begin Trading on a Split-Adjusted Basis on October 23, 2026 HONG KONG, October 21, 2026 - Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (“Ping An Bio” or the “Company”) announced that its board of directors has approved a 1-for-40 reverse stock split of the Company’s class A ordinary shares and class B ordinary shares. The Company’s class A ordinary shares are expected to begin trading on…
Read attachment ↗ea030481501ex99-1.htm · 6-K · 2026-09-11
Exhibit 99.1 PING AN BIOMEDICAL CO., LTD INDEX TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TABLE OF CONTENTS For the Six Months Ended March 31, 2026 and 2025 Page Unaudited Condensed Consolidated Balance Sheets as of March 31, 2026 and September 30, 2025 F-2 Unaudited Condensed Consolidated Statements of Income (loss) and …
Read attachment ↗ea029884701ex99-1.htm · 6-K · 2026-07-22
Exhibit 99.1 Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years Hong Kong, July 22, 2026 - Ping An Biomedical Co., Ltd. (Nasdaq: PASW) (hereinafter referred to as “Ping An Biomedical”) announced that it has formally signed a strategic cooperation agreement with Yuan Sheng Mei Yan Health Services (Hainan) Co., Ltd. (hereinafter referred to as “Yuan Sheng Mei Yan”). Under the agreement, Yuan Sheng Mei Yan will serve…
Read attachment ↗